Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Esomeprazole API

Research Esomeprazole API through FDA DMF and China CDE records. Check the free-form identity, compare reported companies and read the original registry fields before assessing a potential source.

All records in this profile are visible free. An active subscription enables search, status filters and export tools.

This Esomeprazole profile covers the S enantiomer in its free form, CAS 119141-88-7. Esomeprazole magnesium, sodium, potassium and other salts, salt hydrates, pellets and finished dosage forms are excluded. Records are selected by reported name; each filing’s CAS identity and batch specifications have not been independently verified.

Esomeprazole registration data overview

Esomeprazole registry coverage: 1 FDA API DMF entries and 2 CDE API registrations selected by substance name. All Esomeprazole records in this profile fit within the free preview. A subscription adds search, status filters and CSV export tools.

0 documented company-name correspondences

The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording, including repeated parties. No cross-registry company-name correspondences are documented for this profile.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

Esomeprazole coverage: 1 FDA DMF records and 2 CDE registrations. All selected records are visible free; no additional rows are hidden in this profile.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.

Reported companies in Esomeprazole registry records

Use the Esomeprazole registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.

Showing 0 of 0 available entries.

0 company-name correspondences

No exact company-name correspondences are documented for these snapshots.

Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.

Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.

US REGULATORY RECORDS

Esomeprazole FDA Drug Master Files

Inspect the Esomeprazole filing’s reported holder, original subject, submission date and activity status. The record is a starting point for dossier research; it does not establish manufacturing capability or a currently available supply.

API DMF records: 1. Distinct reported holder names: 1.

1Active (A)

0Inactive (I)

A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.

Showing 1 of 1 available entries.

  • ALIVUS LIFE SCIENCES LTDDMF number 20222Active (A)Record details
    DMF number
    20222
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2007-01-31
    Reported holder
    ALIVUS LIFE SCIENCES LTD
    Reported subject
    ESOMEPRAZOLE
Inclusion criteria
  • Selected Type II records: 1. Each included subject is exactly ESOMEPRAZOLE. Selection by name does not independently confirm CAS 119141-88-7 for the filing.
  • Excludes the other Esomeprazole name matches: magnesium, sodium, potassium and strontium salts, their hydrates or process-qualified forms, and pellets. DMF 20392 reports potassium salt; DMF 39741 reports pellets.
  • The six original source fields are retained. Only the Excel submission date is converted to ISO format. Activity status reflects the June 30, 2026 snapshot, not a live registry lookup.

CHINA REGULATORY RECORDS

Esomeprazole NMPA CDE registrations

Inspect the Esomeprazole registration numbers, original Chinese company fields and reported review status. Expand each Esomeprazole entry to see all source columns, including unfilled cells, packaging and approval references.

2 name-selected API registration records

1Approved or qualifying prior approval (A)

1Technical review not passed or unlinked (I)

CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.

Showing 2 of 2 available entries.

  • 重庆莱美隆宇药业有限公司;重庆莱美隆宇药业有限公司Registration number Y20180001696Technical review not passed or unlinked (I)Record details
    Registration number
    Y20180001696
    Reported substance name
    艾司奥美拉唑
    Reported company names
    重庆莱美隆宇药业有限公司;重庆莱美隆宇药业有限公司
    Reported company addresses
    重庆市长寿区经济技术开发区华南四支路2号;重庆市长寿区经济技术开发区华南四支路2号
    Reported product origin
    Domestic (国产)
    Reported packaging
    1Kg/袋/瓶
    Reported specification
    ——
    Record updated
    2019-03-20
    Joint review status
    Technical review not passed or unlinked (I)
    Reported validity date
    Not provided by source
    Source remarks
    Not provided by source
  • 重庆莱美隆宇药业有限公司Registration number Y20190009862Approved or qualifying prior approval (A)Record details
    Registration number
    Y20190009862
    Reported substance name
    艾司奥美拉唑
    Reported company names
    重庆莱美隆宇药业有限公司
    Reported company addresses
    重庆市长寿区经济技术开发区化南四支路2号
    Reported product origin
    Domestic (国产)
    Reported packaging
    Not provided by source
    Reported specification
    Not provided by source
    Record updated
    Not provided by source
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2028-08-22
    Source remarks
    国药准字H20130094
Inclusion criteria
  • Includes 2 registrations named exactly 艾司奥美拉唑. The name-selected records are associated with this Esomeprazole reference profile; the CSV does not independently verify CAS 119141-88-7 for each entry.
  • Excludes magnesium and sodium entries under both 艾司奥美拉唑 and 埃索美拉唑 naming variants, including specified hydrates, injection-use sodium material and magnesium pellets. Omeprazole registrations are a separate racemic identity.
  • All eleven source columns and original row order are retained. Blank fields remain blank and display as Not provided by source. The reported specification ——, repeated parties, addresses, dates and approval reference 国药准字H20130094 are preserved without inferring missing values or current validity.

Esomeprazole chemical identity

Esomeprazole is the S enantiomer of omeprazole, with S configuration at the sulfur atom. The free form has CAS 119141-88-7. Omeprazole is a racemate containing equal amounts of the R and S enantiomers. Magnesium and sodium salts are separate chemical entities. These reference identifiers describe the page’s scope; registry names alone do not verify the composition of every filing.

CAS number
119141-88-7
KEGG Drug: Esomeprazole

Reference identity of the free form; not an independently verified CAS assignment for each registration.

KEGG Drug identifier
D07917
KEGG Drug: Esomeprazole

Esomeprazole chemical properties

The Esomeprazole free form has the molecular formula and reference masses shown here. A shared formula or mass does not establish identical stereochemistry. Salt formation and hydration change composition; confirm the exact form, assay basis, impurity specification and relevant analytical evidence with the manufacturer.

Molecular formula
C17H19N3O3S
KEGG Drug: Esomeprazole
Molecular weight
345.42 g/mol
KEGG Drug: Esomeprazole
Exact mass
345.1147 Da
KEGG Drug: Esomeprazole

Chemical-form and regulatory resources

Use these references to check Esomeprazole identity, the related racemate and the scope of regulatory records.

Esomeprazole API sourcing questions

What chemical form does this Esomeprazole profile cover?

This page covers the free form, CAS 119141-88-7, with S configuration at sulfur. Its molecular formula is C17H19N3O3S and reference molecular weight is 345.42 g/mol. The chemical identifiers are supported by ChEBI and KEGG; inclusion of a registration is based on its reported substance name.

Is Esomeprazole the same substance as omeprazole?

No. Esomeprazole identifies the S enantiomer, whereas omeprazole is a racemate containing equal amounts of the R and S enantiomers. Their common molecular formula does not make them the same chemical entity. Use the linked omeprazole profile when researching the racemate.

Are Esomeprazole magnesium and sodium included?

No. Magnesium, sodium, potassium and other salts, including salt hydrates, are excluded from this free-form selection. Pellets and finished dosage forms are also excluded. Before comparing materials, establish the precise chemical form and request the applicable specification and analytical evidence.

Which Esomeprazole FDA DMF record is included?

The supplied Q2 2026 list contains DMF 20222, held by ALIVUS LIFE SCIENCES LTD, with subject ESOMEPRAZOLE, Type II and activity status A. Its submission date is January 31, 2007. Other matching subjects describe salts or pellets and are excluded. Type II alone does not identify a filing as a free-form API.

Does an active Esomeprazole DMF establish FDA approval?

No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. The Esomeprazole listing does not prove supplier qualification, manufacturing-site approval, a right to reference the dossier or current availability. Check the current official record and obtain the relevant documentation for your application.

Which CDE Esomeprazole registrations are included?

The export contains two entries named exactly 艾司奥美拉唑: Y20190009862 with status A and Y20180001696 with status I. Both report 重庆莱美隆宇药业有限公司, with the company name repeated in the latter field. Separate registration numbers remain separate records; repeated names do not establish additional suppliers.

What do the CDE A and I status codes mean?

CDE status is independent of FDA activity. A can reflect joint technical review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. These labels describe the supplied Esomeprazole snapshot and require a current official check before reliance.

What can I view before subscribing?

All Esomeprazole records currently selected for this profile are visible in the free preview. You can also download their CSV samples. A subscription adds search, status filtering and export tools across available subscription datasets. It does not reveal additional records in this profile or provide quotations, supplier qualification or live registry monitoring.

ChEBI: Esomeprazole stereochemical identityKEGG Drug: EsomeprazoleFDA DMF list: Q2 2026 snapshotNMPA CDE API registry snapshotChEBI: Omeprazole racemateFDA: Types of Drug Master FilesFDA: Drug Master FilesChina API registration status explained

Data sources

Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.

ChEBI: Esomeprazole stereochemical identity

Open source reference

EMBL-EBI

Defines the S configuration that distinguishes this substance from racemic omeprazole.

View citation evidence

“S configuration at the sulfur atom”

EMBL-EBI

Extract from the definition of CHEBI:50275.

KEGG Drug: Esomeprazole

Open source reference

KEGG

Reports CAS 119141-88-7, formula C17H19N3O3S, molecular weight 345.42 and exact mass 345.1147 for the free form.

View citation evidence

“Esomeprazole (INN)”

KEGG

Name reported in KEGG Drug entry D07917; identifiers and masses are taken from the same entry.

ChEBI: Omeprazole racemate

Open source reference

EMBL-EBI

Explains the racemic identity of the related substance and why its registrations are outside this profile.

View citation evidence

“A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.”

EMBL-EBI

Definition in ChEBI CHEBI:7772.

FDA DMF list: Q2 2026 snapshot

Open source reference

U.S. Food and Drug Administration

The displayed filing comes from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.

View citation evidence

“ESOMEPRAZOLE”

U.S. Food and Drug Administration

Exact subject of DMF 20222 in worksheet 2Q2026-EXCEL, row 19422.

FDA: Drug Master Files

Open source reference

U.S. Food and Drug Administration

Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA statement about DMFs; their technical contents are reviewed with applications that reference them.

FDA: Types of Drug Master Files

Open source reference

U.S. Food and Drug Administration

Type II is broader than APIs, so the reported subject must also be checked.

View citation evidence

“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”

U.S. Food and Drug Administration

FDA Type II category heading.

NMPA CDE API registry snapshot

Open source reference

Center for Drug Evaluation, National Medical Products Administration

The October 5, 2026 export supplies the two name-selected registrations, including company fields, original status codes and unfilled cells.

View citation evidence

“艾司奥美拉唑”

Center for Drug Evaluation, National Medical Products Administration

Exact substance name reported for Y20190009862 and Y20180001696 in the supplied CSV.

China API registration status explained

Open source reference

Liaoning Medical Products Administration

Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.

View citation evidence

“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”

Liaoning Medical Products Administration

Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.

Continue your Esomeprazole API research

Use the Esomeprazole records and chemical identity references to prepare your sourcing review. Compare the original names, read each registry’s status definitions and check the official sources. Subscribe when you need search, status filtering and CSV export tools.

All records in this profile are visible free. An active subscription enables search, status filters and export tools.

Report a data issue

Report an Esomeprazole data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.

Contact data support